{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:01:50Z","timestamp":1761490910059},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1208\/s12249-019-1552-3","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T22:02:34Z","timestamp":1575583354000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Potential Active Targeting of Gatifloxacin to Macrophages by Means of Surface-Modified PLGA Microparticles Destined to Treat Tuberculosis"],"prefix":"10.1208","volume":"21","author":[{"given":"Patricia","family":"Marcianes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Negro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Barcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo","family":"Montejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Fern\u00e1ndez-Carballido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"1552_CR1","unstructured":"WHO. Global tuberculosis report 2018 in http:\/\/www.who.int. 2018. Last accessed June 2018."},{"key":"1552_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cll.2014.02.005","volume":"34","author":"SY Lin","year":"2014","unstructured":"Lin SY, Desmond EP. Molecular diagnosis of tuberculosis and drug resistance. Clin Lab Med. 2014;34:297\u2013314. https:\/\/doi.org\/10.1016\/j.cll.2014.02.005.","journal-title":"Clin Lab Med"},{"key":"1552_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/infdis\/jiu816","volume":"2","author":"H Salamon","year":"2015","unstructured":"Salamon H, Yamaguchi KD, Cirillo DM, et al. Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis. J Infect Dis. 2015;2:50\u20137. https:\/\/doi.org\/10.1093\/infdis\/jiu816.","journal-title":"J Infect Dis"},{"key":"1552_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5772\/45820","volume":"16","author":"K Hirota","year":"2012","unstructured":"Hirota K, Terada H. Endocytosis of particles formulations by macrophages and its application to clinical treatment. INTECH, Open Access Publisher. 2012;16:13\u2013428. https:\/\/doi.org\/10.5772\/45820.","journal-title":"INTECH, Open Access Publisher"},{"key":"1552_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejpb.2014.12.001","volume":"89","author":"B Patel","year":"2015","unstructured":"Patel B, Gupta N, Ahsan F. Particle engineering to enhance of lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. Eur J Pharm Biopharm. 2015;89:163\u201374. https:\/\/doi.org\/10.1016\/j.ejpb.2014.12.001.","journal-title":"Eur J Pharm Biopharm"},{"key":"1552_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.colsurfb.2011.05.032","volume":"87","author":"K Hirota","year":"2011","unstructured":"Hirota K, Hasegawa T, Nakajima T, Makino K, Terada H. Phagostimulatory effect of uptake of PLGA microspheres loaded with rifampicin on alveolar macrophages. Colloids Surf B: Biointerfaces. 2011;87:293\u20138. https:\/\/doi.org\/10.1016\/j.colsurfb.2011.05.032.","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"1552_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/jac\/dkl533","volume":"59","author":"R Sharma","year":"2007","unstructured":"Sharma R, Muttil P, Yadav AB, et al. Uptake of inhalable microparticles affects defense responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother. 2007;59:499\u2013506. https:\/\/doi.org\/10.1093\/jac\/dkl533.","journal-title":"J Antimicrob Chemother"},{"key":"1552_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejps.2007.06.006","volume":"32","author":"P Muttil","year":"2007","unstructured":"Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 2007;32:140\u201350. https:\/\/doi.org\/10.1016\/j.ejps.2007.06.006.","journal-title":"Eur J Pharm Sci"},{"key":"1552_CR9","first-page":"128","volume":"2","author":"R Rustomjee","year":"2008","unstructured":"Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;2:128\u201338.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1552_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1745-6215-13-61","volume":"18","author":"CS Merle","year":"2012","unstructured":"Merle CS, Sismanidis C, Sow OB, et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lesson learnt from the gatifloxacin for TB (OFLOTUB) project. Trials. 2012;18:13\u201361. https:\/\/doi.org\/10.1186\/1745-6215-13-61.","journal-title":"Trials."},{"key":"1552_CR11","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","volume":"17","author":"CS Merle","year":"2014","unstructured":"Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin containing regimen for treating tuberculosis. N Engl J Med. 2014;17:1588\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1315817.","journal-title":"N Engl J Med"},{"key":"1552_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/emi.2016.12","volume":"24","author":"Q Ruan","year":"2016","unstructured":"Ruan Q, Liu Q, Sun F, et al. Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials. Emerg Microbes Infect. 2016;24:1038\u201350. https:\/\/doi.org\/10.1038\/emi.2016.12.","journal-title":"Emerg Microbes Infect"},{"key":"1552_CR13","volume-title":"European Pharmacopeia 9th Edition (9.0). Preparations for inhalations: aerodynamic assessment of fine particles","author":"European Directorate for Quality in Medicines (EDQM)","year":"2016","unstructured":"European Directorate for Quality in Medicines (EDQM). European Pharmacopeia 9th Edition (9.0). Preparations for inhalations: aerodynamic assessment of fine particles. Strasburg: France EDQM; 2016."},{"key":"1552_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijpharm.2007.10.007","volume":"352","author":"A Fernandez-Carballidoa","year":"2008","unstructured":"Fernandez-Carballidoa A, Pastoriza P, Barcia E, et al. PLGA\/PEG-derivative polymeric matrix for drug delivery systemapplications: characterization and cell viability studies. Int J Pharm. 2008;352:50\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.10.007.","journal-title":"Int J Pharm"},{"key":"1552_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/02652040500273902","volume":"22","author":"P Puebla","year":"2005","unstructured":"Puebla P, Pastoriza P, Barcia E, Fern\u00e1ndez-Carballido A. PEG-derivative effectively modifies the characteristics of indomethacin-PLGA microspheres destined to intra-articular administration. J Microencapsul. 2005;22:793\u2013808. https:\/\/doi.org\/10.1080\/02652040500273902.","journal-title":"J Microencapsul"},{"key":"1552_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev.immunol.021908.132620","volume":"27","author":"E Galkina","year":"2009","unstructured":"Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165\u201397. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132620.","journal-title":"Annu Rev Immunol"},{"key":"1552_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/ni.1781","volume":"10","author":"DG Russel","year":"2009","unstructured":"Russel DG, Cardona PJ, Kim MJ, et al. F. Foamy macrophages and the progression of the human TB granuloma. Nat. Immunol. 2009;10:943\u20138. https:\/\/doi.org\/10.1038\/ni.1781.","journal-title":"Immunol."},{"key":"1552_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060989","volume":"8","author":"P Pacheco","year":"2013","unstructured":"Pacheco P, White D, Sulchek T. Effects of microparticle size and Fc density on macrophage phagocytosis. PLoS One. 2013;8:e60989. https:\/\/doi.org\/10.1371\/journal.pone.0060989.","journal-title":"PLoS One"},{"key":"1552_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/10611860600834375","volume":"14","author":"S Chono","year":"2006","unstructured":"Chono S, Tanino T, Seki T, Morimoto K. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target. 2006;14:557\u201366. https:\/\/doi.org\/10.1080\/10611860600834375.","journal-title":"J Drug Target"},{"key":"1552_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jconrel.2007.01.013","volume":"119","author":"K Hirota","year":"2007","unstructured":"Hirota K, Hasegawa T, Hinata H, Ito F, Inagawa H, Kochi C, et al. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J Control Release. 2007;119:69\u201376. https:\/\/doi.org\/10.1016\/j.jconrel.2007.01.013.","journal-title":"J Control Release"},{"key":"1552_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ijpharm.2012.07.006","volume":"440","author":"T Sim\u00f3n-Yarza","year":"2012","unstructured":"Sim\u00f3n-Yarza T, Formiga FR, Tamayo E, Pelacho B, Prosper F, Blanco-Prieto MJ. PEGylated-PLGA microparticles containing VEGF for long term drug delivery. Int J Pharm. 2012;440:13\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.07.006.","journal-title":"Int J Pharm"},{"key":"1552_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2014.02.037","volume":"465","author":"R Mathaes","year":"2014","unstructured":"Mathaes R, Winter G, Besheer A, et al. Influence of particle geometry and PEGylation on phagocytosis of particulate carriers. Int J Pharm. 2014;465:1\u20136. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.02.037.","journal-title":"Int J Pharm"},{"key":"1552_CR23","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1073\/pnas.0600997103","volume":"103","author":"S Champion","year":"2006","unstructured":"Champion S, Mitragotri A. Role of target geometry in phagocytosis. Proc Natl Acad Sci. 2006;103:4930\u20134. https:\/\/doi.org\/10.1073\/pnas.0600997103.","journal-title":"Proc Natl Acad Sci"},{"key":"1552_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0168-3659(01)00549-1","volume":"79","author":"F Ahsan","year":"2002","unstructured":"Ahsan F, Rivas IP, Khan MA, et al. Targeting to macrophages: role of physicochemical properties of particulate carriers liposomes and microspheres on the phagocytosis by macrophages. J Control Release. 2002;79:29\u201340. https:\/\/doi.org\/10.1016\/S0168-3659(01)00549-1.","journal-title":"J Control Release"},{"key":"1552_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s13346-013-0176-5","volume":"3","author":"J Verhoef","year":"2003","unstructured":"Verhoef J, Anchordoquy TJ. Questioning the use of PEGylation for drug delivery. Drug Deliv Transl Res. 2003;3:499\u2013503.","journal-title":"Drug Deliv Transl Res"},{"key":"1552_CR26","doi-asserted-by":"publisher","first-page":"12203","DOI":"10.1021\/acsami.6b16556","volume":"9","author":"C Yang","year":"2017","unstructured":"Yang C, Gao S, Dagn\u00e6s-Hansen F, Jakobsen M, Kjems J. Impact of PEG chain length on the physical properties and bioactivity of PEGylated chitosan\/ siRNA nanoparticles in vitro and in vivo. ACS Appl Mater Interfaces. 2017;9:12203\u201316. https:\/\/doi.org\/10.1021\/acsami.6b16556.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1552_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","volume":"307","author":"DE Owens","year":"2006","unstructured":"Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93\u2013102. https:\/\/doi.org\/10.1016\/j.ijpharm.2005.10.010.","journal-title":"Int J Pharm"},{"key":"1552_CR28","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1023\/A:1012248721523","volume":"18","author":"C Mosqueira","year":"2001","unstructured":"Mosqueira C, Legrand P, Morgat J, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res. 2001;18:1411\u20139.","journal-title":"Pharm Res"},{"key":"1552_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1084\/jem.184.2.627","volume":"184","author":"LA Allen","year":"1996","unstructured":"Allen LA, Aderem A. Molecular definition of distinct cytoskeletal structures involved in complement and Fc receptor mediated phagocytosis in macrophages. J Exp Med. 1996;184:627\u201337.","journal-title":"J Exp Med"},{"key":"1552_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0952-7915(01)00309-0","volume":"14","author":"S Greenberg","year":"2002","unstructured":"Greenberg S, Grinstein S. Phagocytosis and innate immunity. Curr Opin Immunol. 2002;14:136\u201345. https:\/\/doi.org\/10.1016\/S0952-7915(01)00309-0.","journal-title":"Curr Opin Immunol"},{"key":"1552_CR31","first-page":"1209","volume":"50","author":"MJ Telko","year":"2005","unstructured":"Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50:1209\u201327.","journal-title":"Respir Care"},{"key":"1552_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1201\/b13340","volume-title":"Pathology for surgeons in training. An A-Z Revision Text","author":"DL Gardner","year":"2002","unstructured":"Gardner DL, Tweedle DEF. Pathology for surgeons in training. An A-Z Revision Text. 3th ed. Boca Raton: Taylor & Francis Group; 2002. p. 32.","edition":"3"},{"key":"1552_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.arbr.2012.02.006","volume":"48","author":"A Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez A, Casan P. Deposition of inhaled particles in the lungs. Arch Bronconeumol. 2012;48:240\u20136. https:\/\/doi.org\/10.1016\/j.arbr.2012.02.006.","journal-title":"Arch Bronconeumol"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-019-1552-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:06:20Z","timestamp":1607040380000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-019-1552-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1208\/s12249-019-1552-3","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]},"assertion":[{"value":"5 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All animal procedures were conducted according to the European Community Council Directive (010\/63\/UE).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"15"}}